Earnings Call · Q1 FY2022·2022-05-05

Q1 22EPS -15.73%·Rev n/aQ4 21EPS -30.25%·Rev n/aQ3 21EPS -31.82%·Rev n/aQ2 21EPS -28.57%·Rev n/a⚠ consensus missing

Ultragenyx Pharmaceutical Inc. RARE

Joshua Higa — Director of Investor Relations

Emil Kakkis — CEO

Erik Harris — Head of Commercialization

Mardi Dier — Chief Financial Officer

Camille Bedrosian — Clinical Program Leader

−13.4%1d on move date−12.8% vs SPY3d−19.4%5d−24.1%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more RARE calls or request research access.

More RARE calls Browse calls Request research access